Form 4: CalciMedica Director Robert Wilson Granted New Stock Options

CalciMedica, Inc. Director Robert N. Wilson was granted a total of 68,593 stock options with exercise prices of $1.53 and $1.65, following stockholder approval of the Amended 2023 Equity Incentive Plan.

Summary

• Robert N. Wilson, a Director of CalciMedica, Inc. (CALC), acquired new stock options on June 24, 2025.
• The options include 10,000 shares with an exercise price of $1.53, vesting 1/12th monthly over one year from March 26, 2025.
• An additional 12,031 shares were granted with an exercise price of $1.53, which are immediately exercisable.
• A grant of 36,562 shares with an exercise price of $1.53 will vest 1/9th monthly over one year from April 1, 2025.
• Lastly, 10,000 shares were granted with an exercise price of $1.65, vesting 1/12th monthly over one year from June 24, 2025, and fully vested by the Company's 2026 annual meeting of stockholders.
• All options have an expiration date of April 22, 2035 (for $1.53 options) or June 23, 2035 (for $1.65 option).
• The option grants were approved by the Board of Directors on April 23, 2025, contingent on stockholder approval of the Company's 2023 Equity Incentive Plan amendment, which was obtained on June 24, 2025.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates continued commitment from a director through equity compensation, aligning their interests with shareholders. It's a routine transaction, so not highly impactful on its own.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• Stockholder approval of the Amended 2023 Equity Incentive Plan demonstrates shareholder support for the company's compensation strategy.

Future Outlook

The document primarily details a past transaction (option grant) and its vesting schedule, which extends into the future. It implies continued director involvement and alignment with the company's long-term performance through equity incentives.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the grant of stock options to a director as part of their compensation. Such grants are common practice across various industries to incentivize and retain key personnel, aligning their financial interests with the company's success.

Corporate Governance

Related Party Transactions

• The stock option grants to Robert N. Wilson, a Director of CalciMedica, Inc., constitute a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The granting of stock options to a director aims to align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees (specifically Director): Robert N. Wilson benefits directly through increased equity ownership and potential future gains from the options.

Next Steps

• Continued vesting of the granted stock options according to their respective schedules.
• The Company's 2026 annual meeting of stockholders, by which certain options will be fully vested.

Key Dates

Keywords

CalciMedica, CALC, Stock Options, Director Compensation, Equity Incentive Plan, Insider Transaction, Form 4, Executive Compensation